## **Ute-Christiane Meier**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6624928/publications.pdf

Version: 2024-02-01

201385 233125 7,507 51 27 45 citations h-index g-index papers 54 54 54 17320 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Vitamin D levels in children and adolescents with chronic tic disorders: a multicentre study. European Child and Adolescent Psychiatry, 2022, 31, 1-12.	2.8	12
2	A role for pathogen risk factors and autoimmunity in encephalitis lethargica?. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 109, 110276.	2.5	2
3	Mycoplasma pneumoniae IgG positivity is associated with tic severity in chronic tic disorders. Brain, Behavior, and Immunity, 2021, 99, 281-288.	2.0	6
4	Cumulative Roles for Epstein-Barr Virus, Human Endogenous Retroviruses, and Human Herpes Virus-6 in Driving an Inflammatory Cascade Underlying MS Pathogenesis. Frontiers in Immunology, 2021, 12, 757302.	2.2	27
5	Risk of Schizophrenia and Bipolar Disorder in Patients With Multiple Sclerosis: Record-Linkage Studies. Frontiers in Psychiatry, 2020, 11, 662.	1.3	8
6	European Multicentre Tics in Children Studies (EMTICS): protocol for two cohort studies to assess risk factors for tic onset and exacerbation in children and adolescents. European Child and Adolescent Psychiatry, 2019, 28, 91-109.	2.8	36
7	Pronounced immunological abnormalities in unmedicated first episode as compared to chronic schizophrenia patients. Neurology Psychiatry and Brain Research, 2019, 34, 58-63.	2.0	o
8	A phase II baseline versus treatment study to determine the efficacy of raltegravir (Isentress) in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium-enhanced MRI: The INSPIRE study. Multiple Sclerosis and Related Disorders, 2018, 24, 123-128.	0.9	25
9	Prodromal symptoms of multiple sclerosis in primary care. Annals of Neurology, 2018, 83, 1162-1173.	2.8	98
10	Depletion of CD20 B cells fails to inhibit relapsing mouse experimental autoimmune encephalomyelitis. Multiple Sclerosis and Related Disorders, 2017, 14, 46-50.	0.9	18
11	Untreated relapsing remitting multiple sclerosis patients show antibody production against latent Epstein Barr Virus (EBV) antigens mainly in the periphery and innate immune IL-8 responses preferentially in the CNS. Journal of Neuroimmunology, 2017, 306, 40-45.	1.1	17
12	Seasonal temperature is associated with Parkinson's disease prescriptions: an ecological study. International Journal of Biometeorology, 2017, 61, 2205-2211.	1.3	6
13	Vitamin-D Deficiency As a Potential Environmental Risk Factor in Multiple Sclerosis, Schizophrenia, and Autism. Frontiers in Psychiatry, 2017, 8, 47.	1.3	59
14	Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, jnnp-2014-309690.	0.9	90
15	Early changes within the lymphocyte population are associated with the development of multiple organ dysfunction syndrome in trauma patients. Critical Care, 2016, 20, 176.	2.5	51
16	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	4.3	4,701
17	Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. Multiple Sclerosis Journal, 2015, 21, 1013-1024.	1.4	249
18	Disposable MMP-9 sensor based on the degradation of peptide cross-linked hydrogel films using electrochemical impedance spectroscopy. Biosensors and Bioelectronics, 2015, 68, 660-667.	5.3	69

#	Article	IF	CITATIONS
19	Unaltered frequency and functionality of CD56bright and CD56dim natural killer cells in untreated relapsing–remitting multiple sclerosis patients. Journal of Neuroimmunology, 2014, 275, 46.	1.1	0
20	Detection of antibodies against the N-methyl-d-aspartate receptor in a sub-group of patients diagnosed with Tourette's syndrome. Journal of Neuroimmunology, 2014, 275, 98.	1.1	1
21	Hypovitaminosis-D and EBV: no interdependence between two MS risk factors in a healthy young UK autumn cohort. Multiple Sclerosis Journal, 2014, 20, 751-753.	1.4	14
22	Epstein–Barr virus, latitude and multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 362-365.	1.4	30
23	The risk of developing multiple sclerosis in individuals seronegative for Epstein-Barr virus: a meta-analysis. Multiple Sclerosis Journal, 2013, 19, 162-166.	1.4	139
24	Month of Birth and Thymic Output. JAMA Neurology, 2013, 70, 527.	4.5	19
25	Early Growth Response Gene-2 Controls IL-17 Expression and Th17 Differentiation by Negatively Regulating Batf. Journal of Immunology, 2013, 190, 58-65.	0.4	57
26	Association of innate immune activation with latent Epstein-Barr virus in active MS lesions. Neurology, 2012, 78, 15-23.	1.5	119
27	131â€Do siblings of people with multiple sclerosis (MS) have markers of MS risk?. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, e1.83-e1.	0.9	0
28	Cell death pathways and autophagy in the central nervous system and its involvement in neurodegeneration, immunity and central nervous system infection: to die or not to die - that is the question. Clinical and Experimental Immunology, 2012, 168, 52-57.	1.1	49
29	Can latent Epstein-Barr virus infection in the central nervous system contribute to neuroinflammation?. Neurology Psychiatry and Brain Research, 2012, 18, 71.	2.0	0
30	Vitamin D: a link between Epstein–Barr virus and multiple sclerosis development?. Expert Review of Neurotherapeutics, 2011, 11, 1221-1224.	1.4	21
31	Viral pathophysiology of multiple sclerosis: A role for Epstein-Barr virus infection?. Pathophysiology, 2011, 18, 13-20.	1.0	19
32	More to come: Humoral immune responses in MS. Journal of Neuroimmunology, 2011, 240-241, 13-21.	1.1	7
33	Vitamin D deficiency–do we follow our own advice?. Clinical Medicine, 2011, 11, 521-523.	0.8	0
34	Role of the HLA System in the Association Between Multiple Sclerosis and Infectious Mononucleosis. Archives of Neurology, 2011, 68, 469.	4.9	17
35	Epstein-Barr virus in the multiple sclerosis brain: a controversial issuereport on a focused workshop held in the Centre for Brain Research of the Medical University of Vienna, Austria. Brain, 2011, 134, 2772-2786.	3.7	176
36	Translational Mini-Review Series on B cell subsets in disease. B cells in multiple sclerosis: drivers of disease pathogenesis and Trojan horse for Epstein–Barr virus entry to the central nervous system?. Clinical and Experimental Immunology, 2011, 167, 1-6.	1.1	37

#	Article	IF	CITATIONS
37	Epstein–Barr Virus and Multiple Sclerosis. , 2011, , 25-37.		1
38	Multiple sclerosis: risk factors, prodromes, and potential causal pathways. Lancet Neurology, The, 2010, 9, 727-739.	4.9	459
39	Epstein Barr virus is not a characteristic feature in the central nervous system in established multiple sclerosis. Brain, 2010, 133, e137-e137.	3.7	132
40	Sickness behaviour is induced by a peripheral CXC-chemokine also expressed in Multiple Sclerosis and EAE. Brain, Behavior, and Immunity, 2010, 24, 738-746.	2.0	41
41	Regulation of autoimmune encephalomyelitis by toll-like receptors. Autoimmunity Reviews, 2009, 8, 506-509.	2.5	69
42	Th1 Polarization of CD4+ T Cells by Toll-Like Receptor 3-Activated Human Microglia. Journal of Neuropathology and Experimental Neurology, 2007, 66, 848-859.	0.9	30
43	Shared Alterations in NK Cell Frequency, Phenotype, and Function in Chronic Human Immunodeficiency Virus and Hepatitis C Virus Infections. Journal of Virology, 2005, 79, 12365-12374.	1.5	161
44	Frequency and Phenotype of Circulating $\hat{Vl}\pm 24/\hat{Vl}^211$ Double-Positive Natural Killer T Cells during Hepatitis C Virus Infection. Journal of Virology, 2003, 77, 2251-2257.	1.5	101
45	A Novel Approach to Antigen-Specific Deletion of CTL with Minimal Cellular Activation Using $\hat{l}\pm 3$ Domain Mutants of MHC Class I/Peptide Complex. Immunity, 2001, 14, 591-602.	6.6	70
46	Reconstitution of antigen presentation in HLA class I-negative cancer cells with peptide-Î <sup>2</sup> 2m fusion molecules. European Journal of Immunology, 2001, 31, 440-449.	1.6	28
47	The influence of antigenic variation on cytotoxic T lymphocyte responses in HIV-1 infection. Journal of Molecular Medicine, 1998, 76, 699-708.	1.7	37
48	The effects of natural altered peptide ligands on the whole blood cytotoxic T lymphocyte response to human immunodeficiency virus. European Journal of Immunology, 1995, 25, 1927-1931.	1.6	75
49	Cytotoxic T Lymphocyte Lysis Inhibited by Viable HIV Mutants. Science, 1995, 270, 1360-1362.	6.0	107
50	The Cleavage of the Bait Region of ?2-Macroglobulin by Human Immunodeficiency Virus Proteinases and by Astacin. Annals of the New York Academy of Sciences, 1994, 737, 431-433.	1.8	5
51	α <sub>2</sub> -Macroglobulin is Cleaved by HIV-1 Protease in the Bait Region but not in the C-Terminal Inter-Domain Region. Biological Chemistry Hoppe-Seyler, 1991, 372, 1051-1056.	1.4	12